Bausch Health Companies’s gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, is presenting new scientific data, including seven posters at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting in San Antonio (Oct. 25 – 30, 2019).
One of the presentations evaluating investigative data on the safety and efficacy of Trulance (plecanatide) was selected as a Presidential Poster Award recipient, the company said in the press release Monday.
Trulance (plecanatide) 3 mg tablets is indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).
“It is our ongoing commitment to R&D that has enabled Salix to produce what the ACG Committee recognizes as high-quality, novel, unique and interesting research,” said Howard Franklin, vice president of Medical Affairs and Strategy, Salix Pharmaceuticals. “We’re especially pleased that a poster presentation featuring Trulance, the newest addition to our portfolio, received the Presidential Poster Award, a distinction that is reserved for only a small percentage of accepted abstracts.”